![]() |
![]() |
My Amedeo
![]() ![]() ![]() |
![]() |
|||||||||
Stroke prevention |
Leukemia |
Free Subscription
1 Acta Haematol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Leukemia is free of charge.
Dramatic recovery after etoposide phosphate infusion for hemophagocytic
lymphohistiocytosis/macrophage activation syndrome following treatment with
tisagenlecleucel in a young patient with relapsed acute lymphoblastic leukemia: a
case report.
Acta Haematol. 2022 Jun 20. pii: 000525576. doi: 10.1159/000525576.
PubMed
Abstract available
Rate of major bleeding with ibrutinib versus bendamustine-rituximab in chronic
lymphocytic leukemia: a population-based cohort study.
Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26632.
PubMed
Blinatumomab Is Associated with Favorable Outcomes in Patients With B-cell
Lineage Acute Lymphoblastic Leukemia and Positive Measurable Residual Disease at
a Threshold of 10(-4) and Higher.
Am J Hematol. 2022 Jun 17. doi: 10.1002/ajh.26634.
PubMed
Abstract available
Human leukocyte antigen-haploidentical transplantation for relapsed/refractory
acute myeloid leukemia: Better leukemia-free survival with bone marrow than with
peripheral blood stem cells in patients >/=55 years of age.
Am J Hematol. 2022 Jun 13. doi: 10.1002/ajh.26627.
PubMed
Abstract available
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid
leukemia: a real-world, multi-center, matched analysis.
Ann Hematol. 2022 Jun 24. pii: 10.1007/s00277-022-04895.
PubMed
Abstract available
Venetoclax in combination with FLAG-IDA-based protocol for patients with acute
myeloid leukemia: a real-world analysis.
Ann Hematol. 2022 Jun 23. pii: 10.1007/s00277-022-04883.
PubMed
Abstract available
Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell
acute lymphoblastic leukemia: a systematic review and meta-analysis.
Ann Hematol. 2022 Jun 21. pii: 10.1007/s00277-022-04880.
PubMed
Abstract available
Clinical characteristics and outcomes of 100 adult patients with pure red cell
aplasia.
Ann Hematol. 2022;101:1493-1498.
PubMed
Abstract available
Durable response of therapy-related MDS/AML with concomitant Waldenstrom's
macroglobulinemia treated with venetoclax and azacitidine.
Ann Hematol. 2022;101:1587-1589.
PubMed
Reply to the Letter to the Editor "Risk of MDS/AML with the addition of
neoadjuvant carboplatin to standard chemotherapy for triple negative breast
cancer" by A. Okines and N. Turner.
Ann Oncol. 2022 Apr 4. pii: S0923-7534(22)00671.
PubMed
Impact of diagnostic genetics on remission MRD and transplantation outcomes in
older patients with AML.
Blood. 2022;139:3546-3557.
PubMed
Abstract available
Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel
high-risk subtype of B-cell ALL.
Blood. 2022;139:3505-3518.
PubMed
Abstract available
Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
Blood. 2022;139:3474-3479.
PubMed
Abstract available
Genetics and outcome in older AML transplant.
Blood. 2022;139:3559.
PubMed
Transplant in older adults with AML: genomic wheat and chaff.
Blood. 2022;139:3459-3461.
PubMed
Why B(-)other? About the gap of unknowns in ALL.
Blood. 2022;139:3455-3457.
PubMed
Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia.
Blood. 2022 Jun 16. pii: 485590. doi: 10.1182/blood.2021015325.
PubMed
Abstract available
Al-Sawaf O, Lilienweiss E, Bahlo J, et al. High efficacy of venetoclax plus
obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.
Blood. 2020;135(11):866-870.
Blood. 2022;139:3669.
PubMed
Plasma cell leukemia with small cell morphology.
Blood. 2022;139:3667.
PubMed
Controversies about immunoglobulin replacement therapy in HSCT recipients with
hypogammaglobulinemia.
Bone Marrow Transplant. 2022;57:874-880.
PubMed
Abstract available
Venetoclax-based regimens in combination with trametinib for RAS-mutated relapsed
or refractory myeloid malignancies.
Bone Marrow Transplant. 2022;57:1034-1037.
PubMed
Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR
analysis.
Bone Marrow Transplant. 2022;57:911-917.
PubMed
Abstract available
Prognostic value of a new clinically-based classification system in patients with
CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP.
Bone Marrow Transplant. 2022;57:896-902.
PubMed
Abstract available
Ph-like gene alterations and complex chromosomal abnormalities are frequent in
patients with acute lymphoblastic leukemia experiencing relapse after allogeneic
hematopoietic cell transplantation.
Eur J Haematol. 2022 Jun 14. doi: 10.1111/ejh.13814.
PubMed
Activin A downregulates the CD69-MT2A axis via p38MAPK to induce erythroid
differentiation that sensitizes BCR-ABL-positive cells to imatinib.
Exp Cell Res. 2022;417:113219.
PubMed
Abstract available
m(6)A RNA modifications: Key regulators of normal and malignant hematopoiesis.
Exp Hematol. 2022;111:25-31.
PubMed
Abstract available
Recurrent transcriptional responses in AML and MDS patients treated with
decitabine.
Exp Hematol. 2022;111:50-65.
PubMed
Abstract available
Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia
patients relapsed after allogeneic hematopoietic stem cell transplantation.
Int J Hematol. 2022 Jun 23. pii: 10.1007/s12185-022-03398.
PubMed
Abstract available
Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia
Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor
Study.
J Clin Oncol. 2022 Jun 22:JCO2102829. doi: 10.1200/JCO.21.02829.
PubMed
Abstract available
Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is
Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial.
J Clin Oncol. 2022 Jun 17:JCO2200245. doi: 10.1200/JCO.22.00245.
PubMed
Abstract available
Clinical Significance of MicroRNA-29a and MicroRNA-100 Gene Expression in
Pediatric Acute Myeloid Leukemia: Erratum.
J Pediatr Hematol Oncol. 2022;44:272.
PubMed
Phyllodes Tumor as a Secondary Neoplasm in Survivors of Childhood Cancer: A
Tertiary Care Cancer Centre Experience.
J Pediatr Hematol Oncol. 2022;44:264-267.
PubMed
Abstract available
Bortezomib-based Anthracycline-free Induction for Pediatric Relapsed ALL as a
Bridge to Immunotherapy.
J Pediatr Hematol Oncol. 2022;44:e896-e900.
PubMed
Abstract available
Identification of Copper Transporter 1 as a Receptor for Feline Endogenous
Retrovirus ERV-DC14.
J Virol. 2022;96:e0022922.
PubMed
Abstract available
Characteristics of SARS-CoV-2 infection in lymphoma/chronic lymphocytic leukemia
patients during the Omicron outbreak.
Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086249.
PubMed
Hyperleukocytosis associated with delayed presentation among patients with acute
leukemia during the COVID-19 pandemic.
Leuk Lymphoma. 2022 Jun 21:1-4. doi: 10.1080/10428194.2022.2087065.
PubMed
The safety of concurrent intrathecal chemotherapy during blinatumomab in adults
with acute lymphoblastic leukemia.
Leuk Lymphoma. 2022 Jun 21:1-3. doi: 10.1080/10428194.2022.2090555.
PubMed
Off-label venetoclax in combination with hypomethylating agents for
post-allogeneic stem cell transplant acute myeloid leukemia relapse.
Leuk Lymphoma. 2022 Jun 22:1-4. doi: 10.1080/10428194.2022.2090553.
PubMed
Lineage switch from acute myeloid leukemia to acute lymphoblastic leukemia.
Leuk Lymphoma. 2022 Jun 23:1-3. doi: 10.1080/10428194.2022.2064984.
PubMed
Association of insurance types and outcomes in acute promyelocytic leukemia.
Leuk Lymphoma. 2022 Jun 23:1-9. doi: 10.1080/10428194.2022.2090554.
PubMed
Abstract available
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia:
recommendations of the Dutch HOVON CLL working group.
Leuk Lymphoma. 2022 Jun 23:1-14. doi: 10.1080/10428194.2022.2084731.
PubMed
Abstract available
Treatments of Ph-like acute lymphoblastic leukemia: a real-world retrospective
analysis from a single large center in China.
Leuk Lymphoma. 2022 Jun 24:1-11. doi: 10.1080/10428194.2022.2090550.
PubMed
Abstract available
Clinical experience with frontline Hyper-CVAD-based regimens, including
Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated
at a comprehensive cancer center.
Leuk Res. 2022;119:106885.
PubMed
Abstract available
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
N Engl J Med. 2022;386:2399-2411.
PubMed
Genomewide expression and methylation analyses reveal aberrant cell adhesion
signaling in tyrosine kinase inhibitorresistant CML cells.
Oncol Rep. 2022;48.
PubMed
Abstract available
Metagenomic shotgun sequencing of blood to identify bacteria and viruses in
leukemic febrile neutropenia.
PLoS One. 2022;17:e0269405.
PubMed
Abstract available
Lower CXCR3 expression in both patients with neovascular AMD and advanced stages
of chronic myeloproliferative blood cancers.
PLoS One. 2022;17:e0269960.
PubMed
Abstract available
Thank you for your interest in scientific medicine.
This policy is made possible thanks to
a media sponsorship by